Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007

Objective. To describe the frequency of selected antimicrobial resistance patterns among pathogens causing device-associated and procedure-associated healthcare-associated infections (HAIs) reported by hospitals in the National Healthcare Safety Network (NHSN). Methods. Data are included on HAIs (ie, central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated pneumonia, and surgical site infections) reported to the Patient Safety Component of the NHSN between January 2006 and October 2007. The results of antimicrobial susceptibility testing of up to 3 pathogenic isolates per HAI by a hospital were evaluated to define antimicrobial-resistance in the pathogenic isolates. The pooled mean proportions of pathogenic isolates interpreted as resistant to selected antimicrobial agents were calculated by type of HAI and overall. The incidence rates of specific device-associated infections were calculated for selected antimicrobial-resistant pathogens according to type of patient care area; the variability in the reported rates is described. Results. Overall, 463 hospitals reported 1 or more HAIs: 412 (89%) were general acute care hospitals, and 309 (67%) had 200-1,000 beds. There were 28,502 HAIs reported among 25,384 patients. The 10 most common pathogens (accounting for 84% of any HAIs) were coagulase-negative staphylococci (15%), Staphylococcus aureus (15%), Enterococcus species (12%), Candida species (11%), Escherichia coli (10%), Pseudomonas aeruginosa (8%), Klebsiella pneumoniae (6%), Enterobacter species (5%), Acinetobacter baumannii (3%), and Klebsiella oxytoca (2%). The pooled mean proportion of pathogenic isolates resistant to antimicrobial agents varied significantly across types of HAI for some pathogen-antimicrobial combinations. As many as 16% of all HAIs were associated with the following multidrug-resistant pathogens: methicillin-resistant S. aureus (8% of HAIs), vancomycin-resistant Enterococcus faecium (4%), carbapenem-resistant P. aeruginosa (2%), extended-spectrum cephalosporin-resistant K. pneumoniae (1%), extended-spectrum cephalosporin-resistant E. coli (0.5%), and carbapenem-resistant A. baumannii, K. pneumoniae, K. oxytoca, and E. coli (0.5%). Nationwide, the majority of units reported no HAIs due to these antimicrobial-resistant pathogens.

[1]  J. Vincent,et al.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. , 1995, JAMA.

[2]  National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986-April 1998, issued June 1998. , 1998, American journal of infection control.

[3]  M. Pfaller,et al.  Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Nnis System,et al.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System. , 1999, American journal of infection control.

[5]  R. Gaynes,et al.  Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Pfaller,et al.  Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. , 2000, International journal of antimicrobial agents.

[7]  J Edwards,et al.  Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999. , 2001, American journal of infection control.

[8]  J. Verhoef,et al.  Frequency of Isolation and Antimicrobial Resistance of Gram-Negative and Gram-Positive Bacteria from Patients in Intensive Care Units of 25 European University Hospitals Participating in the European Arm of the SENTRY Antimicrobial Surveillance Program 1997–1998 , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[9]  J. Verhoef,et al.  Frequency of Isolation of Pathogens from Bloodstream, Nosocomial Pneumonia, Skin and Soft Tissue, and Urinary Tract Infections Occurring in European Patients , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[10]  R. Gaynes,et al.  Temporal Changes in Prevalence of Antimicrobial Resistance in 23 U.S. Hospitals , 2002, Emerging infectious diseases.

[11]  Nnis System National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[12]  R. Wenzel,et al.  Annals of Clinical Microbiology and Antimicrobials Open Access Emerging Resistance among Bacterial Pathogens in the Intensive Care Unit – a European and North American Surveillance Study (2000–2002) Intensive-care Unitantibiotic Susceptibility , 2022 .

[13]  P. Bradford,et al.  Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. , 2004, American journal of infection control.

[15]  Ronald N. Jones,et al.  Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). , 2004, International journal of antimicrobial agents.

[16]  H. Chambers,et al.  Community-associated MRSA--resistance and virulence converge. , 2005, The New England journal of medicine.

[17]  Clinical,et al.  Analysis and presentation of cumulative antimicrobial susceptibility test data; approved guideline , 2005 .

[18]  Richard Platt,et al.  Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Wonkeun Song,et al.  Prevalence of Newer β-Lactamases in Gram-Negative Clinical Isolates Collected in the United States from 2001 to 2002 , 2006, Journal of Clinical Microbiology.

[20]  R. Gaynes,et al.  Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  S. Leone,et al.  Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist. , 2007, International journal of antimicrobial agents.

[22]  J. Bartlett,et al.  Anti-infective research and development--problems, challenges, and solutions. , 2007, The Lancet. Infectious diseases.

[23]  B. Wickes,et al.  First Report of the Emergence of CTX-M-Type Extended-Spectrum β-Lactamases (ESBLs) as the Predominant ESBL Isolated in a U.S. Health Care System , 2007, Antimicrobial Agents and Chemotherapy.

[24]  J. Edwards,et al.  National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007. , 2007, American journal of infection control.

[25]  J. Quinn,et al.  Antimicrobial Resistance among Gram-Negative Bacilli Causing Infections in Intensive Care Unit Patients in the United States between 1993 and 2004 , 2007, Journal of Clinical Microbiology.

[26]  Y. Carmeli,et al.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. , 2007, The Journal of antimicrobial chemotherapy.

[27]  Ronald N. Jones,et al.  Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. , 2007, Diagnostic microbiology and infectious disease.

[28]  J. Blanco,et al.  Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. , 2007, The Journal of antimicrobial chemotherapy.

[29]  Kelly D Peterson,et al.  National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. , 2008, American journal of infection control.